Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other financing activities (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Other financing activities for 11 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 274.81% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 51.65% year-over-year, with the annual reading at $4.0 million for FY2025, 51.71% up from the prior year.
  • Other financing activities for Q4 2025 was $2.0 million at Theravance Biopharma, up from $678000.0 in the prior quarter.
  • The five-year high for Other financing activities was $5.6 million in Q1 2021, with the low at $347000.0 in Q2 2022.
  • Average Other financing activities over 5 years is $1.1 million, with a median of $662000.0 recorded in 2022.
  • The sharpest move saw Other financing activities tumbled 74.11% in 2022, then surged 274.81% in 2025.
  • Over 5 years, Other financing activities stood at $455000.0 in 2021, then surged by 45.49% to $662000.0 in 2022, then fell by 21.75% to $518000.0 in 2023, then rose by 1.93% to $528000.0 in 2024, then soared by 274.81% to $2.0 million in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at $2.0 million, $678000.0, and $503000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.